Switching From Dupilumab to Lebrikizumab in AD: What Does the Data Tell Us?
Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI, reviews new data on atopic dermatitis (AD) patients who switched to lebrikizumab (Ebyglyss, Lilly) from dupilumab (Dupixent, Sanofi and Regeneron) that was presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. “If you had an […]